Search Results

1 - 2 of 2 items :

  • pharmacokinetics x
  • Life Sciences x
  • Clinical Medicine x
  • Psychiatry, Psychotherapy x
Clear All
Safety of concomitant treatment with Non-Vitamin K Oral Anticoagulants and SSRI/SNRI antidepressants

, Mancuso A, Andò G, et al. Pharmacokinetics of new oral anticoagulants: implications for use in routine care. Expert Opin Drug Metab Toxicol. 2018; 14:1057-1069. 5. Dexxience [EU]. BevyxXa [US] · Venous thromboemolism (VTE) prevention - first line - in at risk adult patients hospitalised for an acute medical illness [Cited 13.01.2019]. Accessible at: https://www.sps.nhs.uk/medicines/betrixaban/ 6. Gelosa P, Castiglioni L, Tenconi M, Baldessin L, Racagni G, Corsini A, et al. Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants

Open access
Adriamycin - efficacy and possible adverse effects

): 270-281. 8. Wcisło G., Korniluk J., Szarlej-Wcisło K., Pawlak W.Z., Nurzyński P., Duchnowska R.: Leczenie chorób nowotworowych czynnikiem martwicy nowotworów – alfa (TNF-alfa). Współczesna Onkologia, 2002; 4: 222–227. 9. Gabizon et al . Pharmacokinetics of Pegylated Liposomal Doxorubicin Review of Animal and Human Studies. Clin Pharmacokinet 2003; 42 (5): 419-436. 10. National Institute for Health and Clinical Excellence; TA91 Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydro-chloride and topotecan (review): Guidance

Open access